Chronic Myelogenous Leukemia (CML) Outcomes

The survival graphs below illustrate outcomes of unrelated donor hematopoietic cell transplants (bone marrow, PBSC, or cord blood transplants — BMT) facilitated by the National Marrow Donor Program (NMDP) for adult patients.

Five-year survival for adult patients (> 18 years of age) transplanted for chronic myelogenous leukemia (CML) using marrow (Figure 1) or peripheral blood stem cells (PBSC) (Figure 2) is significantly increased in patients transplanted in first chronic phase compared to those patients transplanted in accelerated or second chronic phase or those in blastic phase.

A large-scale, multi-center phase III clinical trial is underway to determine if graft source (PBSC or marrow) affects transplant outcomes in unrelated donor transplantation for CML and other hematologic malignancies. The trial is being conducted through the Blood and Marrow Transplant Clinical Trials Network (BMT CTN Study 0201). [1]

Figure 1.
Chronic myelogenous leukemia: Survival of adult marrow myeloablative transplant patients 1998-2006. (NMDP data)

View larger version    Download slide (PPT)

References

1. BMT CTN Protocol 0201 - A Phase III randomized multicenter trial comparing G-CSF mobilized peripheral blood stem cell with marrow transplantation from HLA compatible unrelated donors.
   https://web.emmes.com/study/bmt/protocol/0201__protocol/0201__protocol.html